Literature DB >> 33567847

The value proposition of efficiency discount options: The government employees medical scheme emerald value option case study.

Michael M Willie1, Barry Childs, Gunvant Goolab.   

Abstract

BACKGROUND: The Government Employees Medical Scheme (GEMS) introduced an EDO named the Emerald Value Option (EVO) in January 2017. The option was introduced to contain the cost of care whilst simultaneously improving the quality of care by championing care coordination. AIM: This study aimed to assess the impact of introducing an EDO such as EVO as a cost-containment strategy using contracted provider networks and coordinated care.
SETTING: The study was conducted using aggregated data from GEMS. Government Employees Medical Scheme is a restricted medical scheme available to government employees in South Africa.
METHODS: This is a descriptive pairwise comparison study between the Emerald benefit option (the parent option), which does not have embedded care coordination, and its derivative, EVO.
RESULTS: Membership and claims data for 2018 were analysed. Expenditure per life per month in 2018 on the EVO amounts to R1357.01. After adjusting for the risk profile of beneficiaries on the EVO, expenditure per life per month would be expected to be R1621.73 (based on the conventional Emerald option). This translates to a savings of 16.3%. Similarly, health outcomes for EVO were more favourable than expected, actual admission rates were lower at 23.2% versus 26.2% expected.
CONCLUSIONS: The EVO benefit design has succeeded in lowering the cost of care through network provider contracting and care coordination. The EVO has saved approximately R490 million in healthcare costs in 2018. If applied across the medical schemes industry, it is estimated that EVO contracting, and care coordination principles could save R20 billion per annum.

Entities:  

Keywords:  Emerald Value Option; Government Employees Medical Scheme; cost of care; efficiency discount options; general practitioner consultations; medical schemes; specialist consultations

Mesh:

Year:  2021        PMID: 33567847      PMCID: PMC7876986          DOI: 10.4102/phcfm.v13i1.2292

Source DB:  PubMed          Journal:  Afr J Prim Health Care Fam Med        ISSN: 2071-2928


  8 in total

1.  Primary care in the United States: primary care gatekeeping and referrals: effective filter or failed experiment?

Authors:  Christopher B Forrest
Journal:  BMJ       Date:  2003-03-29

Review 2.  Contribution of primary care to health systems and health.

Authors:  Barbara Starfield; Leiyu Shi; James Macinko
Journal:  Milbank Q       Date:  2005       Impact factor: 4.911

3.  The effect of primary care gatekeepers on the management of patients with chest pain.

Authors:  K J Rask; C Deaton; S D Culler; S A Kohler; D C Morris; W A Alexander; R G Pope; W S Weintraub
Journal:  Am J Manag Care       Date:  1999-10       Impact factor: 2.229

4.  Cost Containment and the Tale of Care Coordination.

Authors:  J Michael McWilliams
Journal:  N Engl J Med       Date:  2016-12-08       Impact factor: 91.245

5.  Coordination between primary and secondary healthcare in Denmark and Sweden.

Authors:  Sarah Wadmann; Martin Strandberg-Larsen; Karsten Vrangbæk
Journal:  Int J Integr Care       Date:  2009-03-12       Impact factor: 5.120

6.  Primary health services at district level in South Africa: a critique of the primary health care approach.

Authors:  Sunitha Dookie; Shenuka Singh
Journal:  BMC Fam Pract       Date:  2012-07-02       Impact factor: 2.497

7.  What is the impact of primary care model type on specialist referral rates? A cross-sectional study.

Authors:  Clare Liddy; Jatinderpreet Singh; Ryan Kelly; Simone Dahrouge; Monica Taljaard; Jamie Younger
Journal:  BMC Fam Pract       Date:  2014-02-03       Impact factor: 2.497

8.  An Innovative Approach to Health Care Delivery for Patients with Chronic Conditions.

Authors:  Janice L Clarke; Scott Bourn; Alexis Skoufalos; Eric H Beck; Daniel J Castillo
Journal:  Popul Health Manag       Date:  2016-08-26       Impact factor: 2.459

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.